Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we discuss how WuXi AppTec has bounced back, despite the tremendous pressure it had been under due to the BIOSECURE Act. Also, we see positive lung cancer data from Nuvalent, and we highlight new two European venture funds.
The need-to-know this morning
- Johnson & Johnson said it is acquiring Halda Therapeutics, a developer of cancer drugs, for $3.05 billion. Halda’s lead pipeline product is a treatment for prostate cancer.
WuXi AppTec thrives as U.S. eases pressure
After nearly two years under threat from Congress, WuXi AppTec is emerging stronger: U.S. lawmakers ultimately stripped company names from the BIOSECURE Act, defusing fears the Chinese contract research giant would be blacklisted. In fact, the company’s U.S. revenues surged 31.9% in the first nine months of 2025 even as China sales stalled, STAT contributor Brian Yang writes.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply